BrainCool AB's (publ) rights issue oversubscribed

The subscription period in BrainCool's rights issue of a maximum of SEK 40.1 million ended on November 13. A total of SEK 42 million was subscribed, a subscription rate of 105%, of which 80% was subscribed with preferential rights. Consequently, no guarantee commitments were needed. BrainCool is allocated SEK 40.1 million before costs associated with the rights issue.

CEO Martin Waleij comments;

-        I would like to thank existing as well as new shareholders. With the proceeds from this rights issue, we are now continuing our marketing efforts in brain cooling in Germany and the US and preparing regulatory market approvals and launch in oncology.

BrainCool has conducted this rights issue without a financial adviser, which has saved the shareholders approximately SEK 3 million.

Subscription and allotment

Through the rights issue, 8 022 380 new shares are issued. Approximately 80 percent of the issue volume was subscribed for with preferential rights and approximately 20 percent of the issue volume was subscribed and allocated to subscribers without preferential rights. Guarantee commitments are not needed to be taken into account.

Settlement notes are scheduled to be sent out today, November 18, 2019.

Shares and share capital

Following the rights issue, the share capital amounts to SEK 2 166 042,73, distributed on 48 134 282 shares. Trading in paid subscribed shares (BTA) continues until the rights issue has been registered by the Swedish Companies Registration Office (Bolagsverket), which is expected to take place at the end of November 2019.

Advisor

The law firm Delphi is BrainCool's legal adviser.

This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on November 18, 2019. 

For more information

Martin Waleij - CEO                                                               
+46 - 733 -93 70 76                                                                                          
E-mail: martin.waleij@braincool.se                       

About BrainCool AB (publ)

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.